Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX

Background: The combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is a very effective chemotherapeutic regimen for unresectable pancreatic cancer. Previous studies have reported that female gender may be a predictor of a better response to FOLFIRINOX. This study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jinkook, Ji, Eunjeong, Jung, Kwangrok, Jung, In Ho, Park, Jaewoo, Lee, Jong-Chan, Kim, Jin Won, Hwang, Jin-Hyeok, Kim, Jaihwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911695/
https://www.ncbi.nlm.nih.gov/pubmed/33573202
http://dx.doi.org/10.3390/jpm11020083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911695/
https://www.ncbi.nlm.nih.gov/pubmed/33573202
http://dx.doi.org/10.3390/jpm11020083

Ejemplares similares